The present invention provides the pharmaceutical use of LPA1 antagonists, for example, ±-halogenated thiophene compounds having a specific structure or pharmacologically acceptable salts thereof, as drugs for the treatment and/or prevention of NASH. A pharmaceutical composition for the treatment and/or prevention of NASH includes, as an active ingredient, an LPA1 antagonist, for example, a compound represented by the general formula (I): wherein R 1 is a hydrogen atom or a methoxy group, R 2 is a hydrogen atom or a C 1 -C 6 alkyl group, X is a halogen atom, and A is a group selected from the group consisting of groups: , or a pharmacologically acceptable salt thereof.
